NMI-500

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNMI-500
Drug Alias NameN/A
ClassificationSmall moleculesDiagnostic agent (In vivo)
Mechanisms of ActionFolate receptor alpha modulatorsTubulin polymerisation promotersMitosis inhibitors
TargetsFolate receptor alphaTubulin
Therapy Area/IndicationsOvarian NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNemucore Medical Innovations
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNemucore Medical Innovations
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A